Lung Neoplasms Clinical Trial
Official title:
Management of Symptoms in Patients With Advanced Lung Cancer: Early Incorporation of Patient and Family to Attention and Care Program in Oncology
There is recent evidence that early palliative care administered to patients helps for their
quality of life (QoL). It is however not part of the standard multidisciplinary treatment.
This study intents to evaluate the effect of early palliative care in patients with advanced
Non-Small Cell Lung Cancer (NSCLC) compared to the standard of care.
The multidisciplinary approach of palliative care for symptom management has an impact on
the quality of life (QoL) of patients and their families. The World Health Organization
(WHO) and the American Society of Clinical Oncology (ASCO) recommend incorporating early
palliative care, simultaneously with cancer treatment. Unfortunately, this recommendation
has not been followed in many cancer centers and late referrals to hospice are still
frequent.
Patients with lung cancer have more symptoms than patients with other cancer. The impact on
QoL and symptom management has acquired a great relevance. However, few studies
demonstrating the benefit of early incorporation of palliative care in the management of
patients with advanced lung cancer have been shown.
Palliative care is defined as the care given to patients with progressive active and
advanced disease, and its main purpose is the relief and prevention of suffering and
improving QoL.
In Mexico, the law defines palliative care as comprehensive care for those illnesses not
responsive to curative treatment and include, but are not limited, to pain and other
symptoms associated with the disease and psychological care, social and spiritual, of the
patients and their families.
Psychological aspects The psychological manifestations in patients with lung cancer are
determined by several factors. Depression and anxiety are the most common psychological
reactions. It has been identified that 25% of cancer patients suffer from major depression
at some point during the course of the disease and has been associated with decreased
survival and QoL. Patients with anxiety disorders become more attached to medical treatment
but seek alternative treatments more often. The main objective of psychological
interventions is reducing maladaptive emotional reactions. In advanced stages, caregivers
also confront stress and depression that could lead to health problems.
Nutritional aspects Malnutrition is reported in 60 to 79% in patients with lung cancer and
is the largest contribution to morbidity and mortality. Cachexia is responsible directly or
indirectly to death in one third of patients. The objectives of nutritional support are:
improving tolerance to specific cancer treatment, decreasing the incidence of complications
and, improving the QoL. Thus, it is necessary to conduct an early diagnosis of nutritional
status in order to design nutritional intervention and improve their sense of comfort and
QoL.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
| Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
| Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
| Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
| Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
| Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|